p55 CDC Inhibitors

Common p55 CDC Inhibitors include, but are not limited to Okadaic Acid CAS 78111-17-8, Cantharidin CAS 56-25-7, Calyculin A CAS 101932-71-2, Endothall CAS 145-73-3 and Thiacloprid CAS 111988-49-9.

p55 CDC, also known as cell division cycle protein 55 (CDC55), is a regulatory subunit of protein phosphatase 2A (PP2A), a holoenzyme that plays a crucial role in the control of cell cycle and the regulation of numerous cellular processes. PP2A is a major serine/threonine phosphatase in cells, and its activity is modulated by regulatory subunits like p55 CDC. These regulatory subunits not only affect substrate specificity but also determine the localization and enzymatic activity of the PP2A complex. The p55 CDC, in particular, is known to be involved in the negative control of cell cycle progression. It is crucial for ensuring that events like DNA replication and mitosis occur in the correct sequence and without errors. An imbalance in its activity can lead to misregulation of the cell cycle, which may contribute to various cellular dysfunctions.

p55 CDC inhibitors are a class of chemical entities designed to specifically target and reduce the activity of the p55 CDC component of the PP2A complex. By inhibiting the function of p55 CDC, these compounds can modulate the overall activity of PP2A, thereby influencing the numerous cellular processes governed by this phosphatase. These inhibitors alter cell cycle progression by impacting the checkpoints and regulatory mechanisms where p55 CDC plays a role. The development of these inhibitors is based on a deep understanding of the molecular interactions and functions associated with p55 CDC. High-throughput screening, structure-activity relationship studies, and molecular modeling are among the methodologies employed to identify and optimize compounds that can effectively target this regulatory subunit. Through these efforts, researchers aim to uncover the nuances of p55 CDC's involvement in cellular processes.